196 related articles for article (PubMed ID: 17435968)
1. Prognostic factors in Vogt-Koyanagi-Harada disease.
Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D; Abu El-Asrar AM
Int Ophthalmol; 2007; 27(2-3):201-10. PubMed ID: 17435968
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.
Abu El-Asrar AM; Al Tamimi M; Hemachandran S; Al-Mezaine HS; Al-Muammar A; Kangave D
Acta Ophthalmol; 2013 Sep; 91(6):e486-93. PubMed ID: 23575246
[TBL] [Abstract][Full Text] [Related]
3. Vogt-Koyanagi-Harada disease in children.
Abu El-Asrar AM; Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D
Eye (Lond); 2008 Sep; 22(9):1124-31. PubMed ID: 17479116
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
5. Complications and prognostic factors in Vogt-Koyanagi-Harada disease.
Read RW; Rechodouni A; Butani N; Johnston R; LaBree LD; Smith RE; Rao NA
Am J Ophthalmol; 2001 May; 131(5):599-606. PubMed ID: 11336934
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
7. Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.
Abu El-Asrar AM; Al Mudhaiyan T; Al Najashi AA; Hemachandran S; Hariz R; Mousa A; Al-Muammar A
Ocul Immunol Inflamm; 2017 Aug; 25(4):475-485. PubMed ID: 27003480
[TBL] [Abstract][Full Text] [Related]
8. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.
Katsuyama A; Kusuhara S; Awano H; Nagase H; Matsumiya W; Nakamura M
BMC Ophthalmol; 2019 Aug; 19(1):179. PubMed ID: 31409322
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
11. Vogt Koyanagi Harada disease: treatment and visual prognosis.
Alam M; Iqbal M; Khan BS; Hussain I
J Coll Physicians Surg Pak; 2013 Oct; 23(10):740-2. PubMed ID: 24112262
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Risk Factors of Recurrent Anterior Uveitis in Initial Acute-Onset Vogt-Koyanagi-Harada Disease.
Lim YJ; Byon I; Kim HW; Park SW; Kwon HJ; Kim E
Korean J Ophthalmol; 2023 Aug; 37(4):299-306. PubMed ID: 37400085
[TBL] [Abstract][Full Text] [Related]
13. The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa.
Khairallah M; Zaouali S; Messaoud R; Chaabane S; Attia S; Ben Yahia S; Hmidi K
Int Ophthalmol; 2007; 27(2-3):125-30. PubMed ID: 17203358
[TBL] [Abstract][Full Text] [Related]
14. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome.
Rubsamen PE; Gass JD
Arch Ophthalmol; 1991 May; 109(5):682-7. PubMed ID: 2025171
[TBL] [Abstract][Full Text] [Related]
15. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
16. Outcome and Prognostic Factors of Phacoemulsification Cataract Surgery in Vogt-Koyanagi-Harada Uveitis.
Ji Y; Hu K; Li C; Li P; Kijlstra A; Eghrari AO; Lei B; Du L; Wan W; Yang P
Am J Ophthalmol; 2018 Dec; 196():121-128. PubMed ID: 30194930
[TBL] [Abstract][Full Text] [Related]
17. Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals.
Iwahashi C; Okuno K; Hashida N; Nakai K; Ohguro N; Nishida K
Jpn J Ophthalmol; 2015 May; 59(3):157-63. PubMed ID: 25808016
[TBL] [Abstract][Full Text] [Related]
18. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.
Concha-Del Río LE; Gómez L; Arellanes-García L
Arch Soc Esp Oftalmol (Engl Ed); 2018 May; 93(5):225-230. PubMed ID: 29258782
[TBL] [Abstract][Full Text] [Related]
19. The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.
Veerappan M; Fleischman D; Ulrich JN; Stinnett SS; Jaffe GJ; Allingham RR
Ocul Immunol Inflamm; 2017 Dec; 25(6):748-752. PubMed ID: 27438521
[TBL] [Abstract][Full Text] [Related]
20. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.
Lai TY; Chan RP; Chan CK; Lam DS
Eye (Lond); 2009 Mar; 23(3):543-8. PubMed ID: 18369377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
